Company intelligence / Profile preview

Mabpro

Bratislava, Bratislava region, Slovakiamabpro.com ↗

Ownership: Private
Development stage: Other

Overview

Mabpro is developing monoclonal antibody-based immunotherapies targeting CAIX for aggressive and hypoxic tumors. Its lead candidate, CA9hu-1, is in Phase 1 clinical trials for metastatic clear cell renal cell carcinoma. The company’s approach leverages the role of CAIX as a marker of tumor hypoxia and resistance to conventional therapies. No published clinical results are available yet.

Therapeutic areas: Oncology
Modalities: Monoclonal antibody
Industry: Biotech

Drug pipeline

1 asset

CA9hu-2

Preclinical

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed.

Beyond the preview

Go deeper on Mabpro.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mabpro.

Explore the full profile